OrganoClick

0,70 SEK

-8,64 %

Mindre end 1K følgere

ORGC

First North Stockholm

Chemicals

Basic Materials

-8,64 %
-45,25 %
-59,30 %
-60,11 %
-59,18 %
-71,26 %
-85,60 %
-93,48 %
-90,19 %

OrganoClick operates in environmental technology. The company offers specialized solutions based on fiber-based materials, where the company develops, produces and markets functional fiber chemistry. The products are mainly used in water-repellent fabrics and primarily in wood treatment to protect against fungal decay and fire. The company was founded in 2006 and has its headquarters in Täby.

Læs mere
Markedsværdi
76,78 mio. SEK
Aktieomsætning
39,78 t SEK
Omsætning
106,19 mio.
EBIT %
-29,73 %
P/E
-
Udbytteafkast, %
-
Omsætning og EBIT-margin

Omsætning mio.

EBIT-% (adj.)

EPS og udbytte

EPS (adj.)

Udbytte %

Finanskalender
6.5
2026

Delårsrapport Q1'26

20.5
2026

Generalforsamling '26

17.7
2026

Delårsrapport Q2'26

ViserAlle indholdstyper

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Eksterne analyser

OrganoClick: Soft end to 2025, better setup into 2026 - ABG

* Q4 sales -16% vs. ABGSCe, miss in GC&MP and FW * NW&FT showing positive signs; we see a return to growth in '26e * We cut '26e-'27e sales by 7% on weaker-than-expected report Q4 results OrganoClick reported Q4 sales of SEK 18m (-16% vs. ABGSCe) and...

OrganoClick
Eksterne analyser

OrganoClick: Positive sales in binders, weak elsewhere - ABG

* Q4 sales SEK 18m (-14% y-o-y), -16% vs. ABGSCe * EBIT adj. of SEK -11m (vs. ABGSCe -5.5m) * NW&FT showing signs of improvement, weaker GC&MP and FW Q4 results Sales came in at SEK 18m (-16% vs. ABGSCe 22m), -14% y-o-y (-14% org.). NW&FT increased sales...

OrganoClick
Eksterne analyser

OrganoClick: Expecting to see early signs of recovery - ABG

* Q4e sales SEK 22m (21m), EBIT adj. SEK -5.5m (-6.9m) * We expect NW&FT to start showing early signs of recovery * Trading at '26e-'27e EV/Sales 2.2x-2.0x Q4 expectations For Q4, we estimate sales of SEK 22m, +2% y-o-y and -3% q-o-q (NW&FT: +7% y-o-...

OrganoClick
Eksterne analyser

OrganoClick: Cost savings to cushion volume headwinds - ABG

* Q3 soft, lower volumes from two major customers* We cut '26e-'27e sales and EBIT by 6% and SEK 6m, respectively* Expect volume recovery to take longer than initially projectedQ3 challenging, but cost savings aheadQ3 sales were lower than expected at...

OrganoClick
Eksterne analyser

OrganoClick: Challenging Q3, but cost-cutting underway - ABG

* Q3 sales SEK 22m (-22% y-o-y), EBIT -6.4m (vs. ABGSCe -4.9m)* Lower volumes from two major customers due to timing effects* Cost savings program of ~SEK 14m announcedQ3 resultsSales came in lower than expected at SEK 22m (-18% vs. ABGSCe 27m), -22%...

OrganoClick
Eksterne analyser

OrganoClick: Expect gains in GCMP, pressure elsewhere - ABG

* Report out on 5 November* Q3e sales of SEK 27m (29m), EBIT SEK -5m (-3m)* GC&MP the bright spot, other segments under pressureQ3 expectationsQ3 marks the beginning of the second half of the year, which is typically weaker for OrganoClick (particularly...

OrganoClick
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.